JP7772715B2 - 治療用ｍｕｓｋ抗体 - Google Patents

治療用ｍｕｓｋ抗体

Info

Publication number
JP7772715B2
JP7772715B2 JP2022563016A JP2022563016A JP7772715B2 JP 7772715 B2 JP7772715 B2 JP 7772715B2 JP 2022563016 A JP2022563016 A JP 2022563016A JP 2022563016 A JP2022563016 A JP 2022563016A JP 7772715 B2 JP7772715 B2 JP 7772715B2
Authority
JP
Japan
Prior art keywords
seq
cdr
antibody
mice
musk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522212A5 (https=
JP2023522212A (ja
Inventor
スティーブン・ジェイ・バーデン
祥平 小出
明子 小出
ナディア・ルループ
ジュリアン・オーリー
カレン・シレンス
ルーラント・ヴァンハウエルト
クリストフ・ブランシェット
クリストフ・ステアール
キャサリーン・メーンズ
バーンハート・ファンケルクホーフェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of JP2023522212A publication Critical patent/JP2023522212A/ja
Publication of JP2023522212A5 publication Critical patent/JP2023522212A5/ja
Priority to JP2025187491A priority Critical patent/JP2026056615A/ja
Application granted granted Critical
Publication of JP7772715B2 publication Critical patent/JP7772715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022563016A 2020-04-17 2021-04-16 治療用ｍｕｓｋ抗体 Active JP7772715B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025187491A JP2026056615A (ja) 2020-04-17 2025-11-06 治療用ｍｕｓｋ抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011986P 2020-04-17 2020-04-17
US63/011,986 2020-04-17
US202063038633P 2020-06-12 2020-06-12
US63/038,633 2020-06-12
US202063112375P 2020-11-11 2020-11-11
US63/112,375 2020-11-11
PCT/US2021/027801 WO2021212053A2 (en) 2020-04-17 2021-04-16 Therapeutic musk antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025187491A Division JP2026056615A (ja) 2020-04-17 2025-11-06 治療用ｍｕｓｋ抗体

Publications (3)

Publication Number Publication Date
JP2023522212A JP2023522212A (ja) 2023-05-29
JP2023522212A5 JP2023522212A5 (https=) 2024-06-21
JP7772715B2 true JP7772715B2 (ja) 2025-11-18

Family

ID=75850676

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563016A Active JP7772715B2 (ja) 2020-04-17 2021-04-16 治療用ｍｕｓｋ抗体
JP2025187491A Pending JP2026056615A (ja) 2020-04-17 2025-11-06 治療用ｍｕｓｋ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025187491A Pending JP2026056615A (ja) 2020-04-17 2025-11-06 治療用ｍｕｓｋ抗体

Country Status (12)

Country Link
US (2) US11492401B2 (https=)
EP (1) EP4136115A2 (https=)
JP (2) JP7772715B2 (https=)
KR (1) KR20230028217A (https=)
CN (1) CN115843268A (https=)
AU (1) AU2021256049A1 (https=)
BR (1) BR112022021065A2 (https=)
CA (1) CA3175597A1 (https=)
IL (1) IL297295A (https=)
MX (1) MX2022011856A (https=)
PH (1) PH12022552483A1 (https=)
WO (1) WO2021212053A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147489A2 (en) * 2022-01-28 2023-08-03 argenx BV Anti-musk antibodies for use in treating neuromuscular disorders
WO2023218099A1 (en) * 2022-05-13 2023-11-16 argenx BV In utero treatment of a fetus having genetic disease/neuromuscular disease
AU2024271522A1 (en) * 2023-05-15 2025-11-20 argenx BV Antibodies for use in agrin-deficient disorders
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521772A (ja) 2010-03-11 2013-06-13 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
US20150050289A1 (en) 2011-11-14 2015-02-19 New York University Muscle specific receptor kinase and modulation thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6737249B1 (en) 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US6624819B1 (en) 2000-05-01 2003-09-23 Broadcom Corporation Method and system for providing a flexible and efficient processor for use in a graphics processing system
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2453822C (en) 2001-08-03 2011-02-22 Tyco Healthcare Group Lp Tissue marking apparatus and method
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
JP2011207769A (ja) 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
US9574015B2 (en) 2013-09-13 2017-02-21 New York University Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521772A (ja) 2010-03-11 2013-06-13 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
US20150050289A1 (en) 2011-11-14 2015-02-19 New York University Muscle specific receptor kinase and modulation thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
eLife，2018年，Vol.7, e34375，pp.1-19
JCI Insight，2017年，Vol.2, No.17, e94263，pp.1-14
JCI Insight，2019年，Vol.4, No.12, e127167，pp.1-17
NATURE BIOTECHNOLOGY，1997年，Vol.15，pp.768-771
NATURE BIOTECHNOLOGY，2010年，Vol.28, No.11，pp.1203-1207, ONLINE METHODS
抗原と抗体の相互作用とは［抗体技術の基本原理］，サイエンス系お役立ちメディア Ｍ－ｈｕｂ，2018年05月28日，インターネット <URL: https://m-hub.jp/biology/1011/interaction-between-antigen-and-antibody>，[検索日 2025年4月1日］

Also Published As

Publication number Publication date
AU2021256049A1 (en) 2022-11-03
BR112022021065A2 (pt) 2023-02-23
JP2026056615A (ja) 2026-04-01
IL297295A (en) 2022-12-01
PH12022552483A1 (en) 2024-02-05
US11492401B2 (en) 2022-11-08
US20220259304A1 (en) 2022-08-18
WO2021212053A3 (en) 2021-11-18
WO2021212053A8 (en) 2022-09-29
MX2022011856A (es) 2023-02-23
CN115843268A (zh) 2023-03-24
WO2021212053A2 (en) 2021-10-21
JP2023522212A (ja) 2023-05-29
CA3175597A1 (en) 2021-10-21
KR20230028217A (ko) 2023-02-28
US20230151091A1 (en) 2023-05-18
EP4136115A2 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
US10875910B2 (en) Antibodies recognizing alpha-synuclein
JP7772715B2 (ja) 治療用ｍｕｓｋ抗体
AU2008334637B2 (en) Antigen binding proteins
JP6744856B2 (ja) α−シヌクレインを認識する抗体を含む血液脳関門シャトル
JP2018148911A (ja) α−シヌクレインを認識するヒト化抗体
EP3558364A1 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US12365724B2 (en) Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
CN119013308A (zh) 用于治疗神经肌肉病症的抗MuSK抗体
WO2023218099A1 (en) In utero treatment of a fetus having genetic disease/neuromuscular disease
US20250188190A1 (en) In utero treatment of a fetus having genetic disease/neuromuscular disease
HK40091546A (zh) 治疗性musk抗体
EA051806B1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ MuSK
AU2024271522A1 (en) Antibodies for use in agrin-deficient disorders
HK1212361B (en) Antibodies recognizing alpha-synuclein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230126

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251106

R150 Certificate of patent or registration of utility model

Ref document number: 7772715

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150